Effects of resveratrol supplementation on serum concentrations of plasminogen activator inhibitor-1, fibroblast growth factor 21, and adiponectin in patients with nonalcoholic fatty liver disease.

ABSTRACT:

Background

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder which may progress from simple steatosis to liver failure. Patients with NAFLD have higher levels of systemic inflammation. Resveratrol, a natural polyphenolic compound, has been shown to have anti-inflammatory effects through various mechanisms. The aim of this study was to evaluate the effect of resveratrol supplementation on serum levels of plasminogen activator inhibitor-1 (PAI-1), adiponectin, fibroblast growth factor-21 (FGF-21) as well as high-sensitivity C-reactive protein (hs-CRP) in patients with NAFLD.

Methods

In this double-blind randomized controlled trial, 50 adults with NAFLD aged 20-60 years were allocated into two groups; the intervention and the placebo group rece

SUBMITTER: Farzin L 

PROVIDER: S-EPMC11809030 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature